Compare GOLF & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOLF | MIRM |
|---|---|---|
| Founded | 1910 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.2B |
| IPO Year | 2016 | 2019 |
| Metric | GOLF | MIRM |
|---|---|---|
| Price | $86.46 | $81.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $74.86 | ★ $95.64 |
| AVG Volume (30 Days) | 302.9K | ★ 854.1K |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 24.30 | N/A |
| EPS | ★ 3.64 | N/A |
| Revenue | ★ $2,526,675,000.00 | $471,794,000.00 |
| Revenue This Year | $5.17 | $53.78 |
| Revenue Next Year | $2.52 | $19.91 |
| P/E Ratio | $23.41 | ★ N/A |
| Revenue Growth | 4.20 | ★ 53.66 |
| 52 Week Low | $55.31 | $36.88 |
| 52 Week High | $87.25 | $83.75 |
| Indicator | GOLF | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 60.97 | 62.99 |
| Support Level | $79.41 | $73.82 |
| Resistance Level | $83.88 | $83.75 |
| Average True Range (ATR) | 2.15 | 3.67 |
| MACD | 0.31 | 0.36 |
| Stochastic Oscillator | 89.13 | 84.74 |
Acushnet Holdings Corp is engaged in the design, development, manufacture, and distribution of golf products. Its product category includes golf balls, golf shoes, golf clubs, wedges, putters, golf gloves, golf gear and golf wear, and others. These products are offered through different brands such as Titleist, FootJoy, Scotty Cemeron, Vokey Design, Pinnacle, KJUS, and others. The company's reportable segments are Titleist golf equipment, FootJoy golf wear, and Gofl gear. A majority of its revenue is generated by the Titleist golf equipment segment. Geographically, the company generates maximum revenue from the United States, followed by Europe, Middle East and Asia (EMEA), Japan, Korea, and the Rest of the world.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.